Rose Capital Advisors LLC Buys New Shares in Ascendis Pharma A/S $ASND

Rose Capital Advisors LLC purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 3,087 shares of the biotechnology company’s stock, valued at approximately $823,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Sapient Capital LLC bought a new position in shares of Ascendis Pharma A/S in the second quarter worth about $24,581,000. Quantitative Investment Management LLC bought a new position in shares of Ascendis Pharma A/S during the 2nd quarter valued at approximately $529,000. Ferguson Wellman Capital Management Inc. bought a new position in shares of Ascendis Pharma A/S during the 2nd quarter valued at approximately $693,000. Braun Stacey Associates Inc. increased its holdings in Ascendis Pharma A/S by 1.3% in the 2nd quarter. Braun Stacey Associates Inc. now owns 132,682 shares of the biotechnology company’s stock worth $35,389,000 after acquiring an additional 1,690 shares in the last quarter. Finally, Dearborn Partners LLC purchased a new stake in Ascendis Pharma A/S in the 2nd quarter worth approximately $347,000.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ASND shares. HC Wainwright initiated coverage on shares of Ascendis Pharma A/S in a report on Thursday, August 27th. They set a “buy” rating and a $345.00 price target on the stock. Stifel Nicolaus reduced their price objective on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Morgan Stanley decreased their price objective on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research report on Tuesday. Wedbush restated an “outperform” rating and set a $327.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, September 1st. Finally, Barclays dropped their target price on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $310.05.

Insider Buying and Selling at Ascendis Pharma A/S

In related news, Director Jean-Jacques Bienaimé bought 2,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average price of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the transaction, the director owned 2,900 shares in the company, valued at $714,357. The trade was a 222.22% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Stock Down 0.2%

NASDAQ ASND opened at $270.56 on Friday. Ascendis Pharma A/S has a 12 month low of $186.05 and a 12 month high of $282.15. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. The stock has a market cap of $16.88 billion, a PE ratio of 20.99 and a beta of 0.35. The stock’s 50 day moving average is $257.84 and its 200 day moving average is $240.69.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The company had revenue of $387.22 million for the quarter, compared to analysts’ expectations of $376.75 million. Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. Research analysts predict that Ascendis Pharma A/S will post 5.15 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.